Navigation Links
Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
Date:4/26/2008

MILAN, Italy, April 26 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). The ongoing study evaluates boceprevir in 28-week and 48-week treatment regimens.

In a 28-week treatment regimen in which patients received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID), the rate of sustained virological response at 12 weeks after the end of treatment (SVR 12) was 57 percent (ITT).(1-3) Importantly, this treatment regimen provided an indication of early predictability of response, with patients who had undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment achieving an SVR 12 rate of 86 percent.

"These interim results are very encouraging, especially given the response seen with a shorter course of therapy in a difficult-to-treat patient population," said principal investigator Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, who presented the data. "Boceprevir has been well tolerated by patients in this study, including in the longer duration treatment arms, and we look forward to further results from this ongoing study."

Overall, 77 percent of the 595 patients in the study were enrolled in the United States. African-Amer
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
2. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
11. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., ... information systems technology, will feature an exhibit booth during ... Meeting and Clinical Lab Expo in ... "We are extremely excited to exhibit ... to interact with our customers and continue the dialogue ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation (Apex, ... Pressure Area Care sectors, announces that it is appealing the ... in Germany that found the ... notes that it has initiated invalidity challenges against various ResMed ... in counterattacking against trivial and junk patents. ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory ... that it is a Bronze winner in the 35th Annual ... Through a Child's Eye and Silverado Resident Visits ... a Child's Eye , seven-year-old Mia Sandoval shares her experience ... a memory care community in Los Angeles. The feel-good video ...
(Date:7/29/2014)... 29, 2014 According to a new ... leading global authority in medical device market research, the ... to over $8 billion by 2018. This growth ... the transcatheter heart valve market, which is comprised of ... transcatheter mitral valve repair (TMVR) segments. , There are ...
(Date:7/29/2014)... 29, 2014 According to the New ... the recreational and the medicinal sectors is mirroring the ... becomes more accepted in mainstream culture, many are turning ... the traditional and more dangerous forms of smoking the ... quite the trend in legalized states such as Colorado ...
(Date:7/29/2014)... 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... to improve access to essential pain medications for people ... ACS, Treat the Pain initiative, this new partnership will ... HIV/AIDS services throughout the country. , Swaziland has ... than 26 percent of adults ages 15-49 infected. Many ...
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:OZ Naturals to Launch Its Products in the UK 2
... planned strategic growth that ... Lansing and Michigan, LANSING, Mich., Oct. 8 In ... Grand River, accommodate up to 500 new jobs for,Lansing and ... subsidiary Accident Fund Insurance Company of America announced,today it will ...
... MURRYSVILLE, Pa., Oct. 8 Dixtal Medical, Inc.,and ... that Dixtal Medical,has acquired the Novametrix pulse oximetry ... will be marketed under the,Dixtal/Novametrix brand pursuant to ... Novametrix, founded in 1978 and acquired,by Respironics in ...
... mean more estrogen, bringing higher odds for the illness, researchers ... and shape of a woman,s hips may affect her daughter,s ... The study of 6,370 Finnish women found that breast cancer ... mothers with relatively wide hips, and nearly seven times higher ...
... Brothers is proud to be the,leading supplier of Official ... extends over 90 years. The embroidered badges and awards,produced ... substances. As a global manufacturer, Lion Brothers maintains ... substances in any of its,manufacturing processes. Lion tests materials ...
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce ... 25. During a conference call on October 25 at ... executives will,address inquiries from investors and analysts. Investors ... a live,webcast of the call at http://www.bms.com/ir ...
... or useless, the appendix now appears to have a reason ... bacteria living in the human gut. , Drawing upon a ... postulate that the beneficial bacteria in the appendix that aid ... evacuates the intestines and emerge afterwards to repopulate the gut. ...
Cached Medicine News:Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 2Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 3Health News:Woman's Hips Might Indicate Daughter's Breast Cancer Risk 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 3
... Drug Interaction Principles is the number one ... , An understanding of drug interactions has ... Since publication of the first edition of ... pharmacopoeia - coupled with prolonged human life ...
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Updated for 2006 with more than 800 complete drug entries, this mobile reference provides instant access to all the drug information nurses need in day-to-day practice....
... ACM-8 loads and unloads two centrifuges with ... via Cap Recognition the tube type is ... batches of three 5 position racks into ... single centrifuge ACM can be offered for ...
Medicine Products: